Abstract:OBJECTIVES:Remifentanil preconditioning attenuates myocardial ischemia reperfusion injury, but the underlying mechanism is incompletely understood. The Janus activated kinase-2 (JAK2)/signal transducers and activators of transcription-3 (STAT3) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways are critical in both ischemic and pharmacologic preconditioning cardioprotection, which involve the inactivation of glycogen synthase kinase-3β. We hypothesized that remifentanil preconditioning confers cardioprotection via the JAK2/STAT3 and/or PI3K/Akt activation-mediated glycogen synthase kinase-3β inhibition. DESIGN:Pharmacologic intervention. SETTING:Research laboratory. SUBJECTS:Male Sprague-Dawley rats. INTERVENTIONS:In vivo and in vitro treatments. MEASUREMENTS AND MAIN RESULTS:Male Sprague-Dawley rats (n = 6 per group) were sham operated or subjected to myocardial ischemia reperfusion injury. The JAK2 inhibitor AG490 (3 mg/kg), the PI3K inhibitor wortmannin (15 μg/kg), or the glycogen synthase kinase-3β inhibitor SB216763 (600 μg/kg) were given before inducing in vivo myocardial ischemia reperfusion injury achieved by occluding coronary artery for 30 minutes followed by 120 minutes of reperfusion in the absence or presence of remifentanil preconditioning (6 μg/kg/min). Also, isolated rat hearts were Langendorff perfused and subjected to 30 minutes of global ischemia and 120 minutes of reperfusion without or with remifentanil preconditioning (100 ng/mL) in the presence or absence of AG490 and/or SB216763. Isolated rat cardiomyocytes and H9C2 cells were subjected to hypoxia/reoxygenation alone or in combination with AG490 (100 μM), wortmannin (100 nM), or SB216763 (3 μM) without or with remifentanil preconditioning (2.5 μM). Remifentanil preconditioning reduced postischemic myocardial infarction and hemodynamic dysfunction induced by myocardial ischemia reperfusion injury concomitant with increased phosphorylation of STAT3 at tyr-705 (p-STAT3) and glycogen synthase kinase-3β but not Akt. AG490 but not wortmannin cancelled remifentanil preconditioning cardioprotection, and SB216763 restored it despite the presence of AG490. In Langendorff-perfused hearts, AG490-mediated cancellation of remifentanil preconditioning cardioprotection in attenuating postischemic myocardial infarction and creatinine kinase-MB release was reverted by concomitant administration of SB216763. Remifentanil preconditioning also attenuated posthypoxic cardiomyocyte injury and increased p-STAT3 and glycogen synthase kinase-3β in isolated primary cardiomyocytes and H9C2 cells. STAT3 gene knockdown with specific synthetic RNA cancelled remifentanil preconditioning cardioprotection, whereas glycogen synthase kinase-3β gene knockdown, which per se did not affect STAT3 under hypoxia/reoxygenation condition, preserved remifentanil preconditioning cardioprotection regardless of STAT3 abrogation. CONCLUSIONS:Remifentanil preconditioning confers cardioprotection primarily via activation of JAK2/STAT3 signaling that can function independent of PI3K/Akt activation. Glycogen synthase kinase-3β is a critical downstream effector of remifentanil preconditioning cardioprotection.

Remifentanil Attenuates Cardiac Dysfunction, Lipid Peroxidation and Immune Disorder in Rats with Isoproterenol-Induced Myocardial Injury Via JNK/NF-KB P65 Inhibition

Remifentanil protects against myocardial ischemia/reperfusion injury via miR-205-mediated regulation of PINK1

Remifentanil Anesthesia on the Expression of Apoptosis-Related Proteins Bcl-2 and Bax in Rat Myocardial Cells with Ischemia-Reperfusion Injury.

Progress in myocardial protective effect of remifentanil

Remifentanil Attenuates Lipopolysaccharide-Induced Oxidative Injury by Downregulating PKCβ2 Activation and Inhibiting Autophagy in H9C2 Cardiomyocytes

High Dose Remifentanil Increases Myocardial Oxidative Stress and Compromises Remifentanil Infarct-Sparing Effects in Rats.

Remifentanil preconditioning reduces hepatic ischemia-reperfusion injury in rats via inducible nitric oxide synthase expression.

Effects of Remifentanil on NF-Bκ Activity in a Rabbit Model of Myocardial Ischemia/reperfusion Injury

Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3β in Rats.

Remifentanil protects liver against ischemia/reperfusion injury through activation of anti-apoptotic pathways.

Remifentanil Preconditioning Confers Cardioprotection Via the Jak/Stat but Not Pi3k/Akt Pathway in Rats

Effects of Different Doses of Remifentanil on Renal Ischemia-Reperfusion Injury in Rats

Effects of Remifentanil on Cell Apoptosis in Ischemia-Reperfusion Injury in Rat Brain

Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1/NF- κ B Signaling Pathway.

Remifentanil Ameliorates Liver Ischemia-Reperfusion Injury Through Inhibition of Interleukin-18 Signaling.

Remifentanil Promotes PDIA3 Expression by Activating P38mapk to Inhibit Intestinal Ischemia/Reperfusion-Induced Oxidative and Endoplasmic Reticulum Stress.

Remifentanil Preconditioning Attenuates Hepatic Ischemia-Reperfusion Injury in Rats Via Neuronal Activation in Dorsal Vagal Complex

Remifentanil Preconditioning Attenuates Hepatic Ischemia and Reperfusion Injury in Rats

The Regulatory Effect of Remifentanil on JNK Signaling during Remission of Flap Ischemia-Reperfusion Injury

Remifentanil preconditioning induces protection against focal cerebral ischemia-reperfusion injury in rats

Remifentanil preconditioning protects against hypoxia-induced senescence and necroptosis in human cardiac myocytes in vitro